Ionis Pharmaceuticals (IONS) had its price target raised by Leerink Partners from $102.00 to $104.00. They now have an "outperform" rating on the stock.
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) [Yahoo! Finance]
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story [Yahoo! Finance]
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance [Yahoo! Finance]
Ionis Pharmaceuticals (IONS) had its price target raised by Piper Sandler from $87.00 to $100.00. They now have an "overweight" rating on the stock.